Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes
S2CID 2584722
Introduction to propensity scores
Less than a month after that Super Bowl ad aired, the FDA began announcing new policies that require compounding pharmacies to stop making compounded semaglutide and tirzepatide (the active ingredients in Ozempic and Mounjaro, respectively), which also meansin theorythat telemedicine companies need to stop selling these drugs
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
weekly), the duration of GLP-1 RAs use, the indication of use (diabetes mellitus vs
